$OSCR

Results: Oscar Health, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Oscar Health, Inc. reported quarterly results that beat expectations, with revenue up 2.7% to $4.9b and statutory profit of $1.10, 212% above analyst forecasts. Analysts updated 2026 consensus to $18.6b revenue and EPS $1.63. The consensus price target rose 12% to $28.20.

Original reporting
Published Aug 10, 2026, 10:34 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Results: Oscar Health, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates — source image
Decision brief

The 30-second read

$OSCRBullishMed
01

Why it matters

Analysts upgraded 2026 EPS expectations and raised the consensus price target, while keeping the 2026 revenue outlook broadly flat, signaling improved profitability expectations rather than faster top-line growth.

02

Market read

Consensus expectations moved toward higher earnings power for 2026, which can influence near-term positioning and valuation multiples.

03

What to watch

The article does not detail underlying drivers of the statutory profit beat (e.g., claims, expenses, reserving), so traders should verify whether the earnings quality is durable before extrapolating.

Relevance 7/10Novelty 5/10Timing: post-earnings, consensus update published today

Background

The piece summarizes Oscar Health’s latest quarterly results and the resulting post-earnings consensus estimates for 2026.

Company-level read

Ticker impact

$OSCRBullishMedium confidence
Context

Oscar Health reported quarterly results with revenue beating expectations by 2.7% to $4.9B and analysts lifted EPS estimates for 2026.

Expected impact

Near-term bias to the upside as the market digests the EPS upgrade and higher consensus price target.

Evidence & confidence

The article cites a 212% statutory profit beat and a consensus EPS upgrade for 2026, alongside a 12% rise in the consensus price target, which typically supports sentiment and positioning.

Market effects

Improves sentiment toward US health insurance/insurtech names by reinforcing that profitability can surprise even when revenue growth is steady.

Limited, primarily affects US small/mid-cap healthcare insurance sentiment.

Low, as the update is company-specific and not tied to global policy or cross-border developments.

Counterpoint

Revenue forecasts are described as essentially unchanged, so the EPS upgrade may be driven by one-off items or assumptions that could reverse.

Key entities

  • Oscar Health, Inc.

    US-listed health insurance/insurtech company whose quarterly results and post-earnings consensus estimates are discussed.

Related articles

$UNHHighAI 8/10

Health Insurer Stocks Are Soaring As Companies Get A Handle On Costs

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

$OSCRHighAI 8/10

Oscar Health stock hits 52-week high at 33.54 USD

Oscar Health (OSCR) hit a 52-week high of $33.54, with a 90.7% total return over the past year. The company reported Q2 2026 adjusted earnings of $1.10 per share, beating estimates of $0.37, and revenue of $4.88 billion, exceeding expectations. InvestingPro suggests the stock may be overvalued, with a high beta of 2.39.

$OSCRHigh

OSCR Stock Hits 5-Year High: Oscar Sees 'Healthy Tailwinds' In 2026 On Potential Upside To Guidance

Oscar Health (OSCR) shares rose 12% to a 5-year high after the company reported strong Q1 earnings and optimistic guidance for 2026. CFO Scott Blackley cited favorable industry trends and potential upside to guidance, with membership growing 56% year-over-year to 3.17 million. The company's medical loss ratio improved to 70.5% from 75.4%. OSCR stock has gained 78% over the past year.

$AAPLMed

Why Did AAPL, OSCR, LLY Stocks Hit 52-Week Highs Today?

Apple shares (AAPL) hit a 52-week high after the company unveiled “Siri AI” at its WWDC, with the assistant using Google Gemini tech. Oscar Health (OSCR) rose to a 52-week high after reaffirming 2026 revenue guidance of $18.7B to $19B. Eli Lilly (LLY) reached a record high on positive late-stage results for oral obesity drug Foundayo and plans to seek U.S. approval for Type 2 diabetes.